| scholarly article | Q13442814 |
| P50 | author | Raphael Leonardo Cunha Araujo | Q84414522 |
| Allan A L Pereira | Q86349615 | ||
| P2093 | author name string | Paulo M Hoff | |
| Rachel P Riechelmann | |||
| Suilane Coelho Ribeiro Oliveira | |||
| Karla T Souza | |||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 |
| Cancer statistics, 2016 | Q29547383 | ||
| Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin | Q30415832 | ||
| Metaprop: a Stata command to perform meta-analysis of binomial data | Q30916914 | ||
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma | Q33729819 | ||
| Capecitabine as adjuvant treatment for stage III colon cancer | Q34429990 | ||
| RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal | Q34478729 | ||
| Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study | Q34514696 | ||
| Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. | Q34603290 | ||
| Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial | Q34637479 | ||
| Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option | Q35678065 | ||
| Impact of the HIV epidemic on the incidence rates of anal cancer in the United States | Q36727400 | ||
| Non-inferiority cancer clinical trials: scope and purposes underlying their design | Q38089532 | ||
| Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial | Q38390829 | ||
| EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer | Q40093033 | ||
| Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial | Q43973278 | ||
| Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study | Q44040804 | ||
| Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal | Q44452471 | ||
| Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study | Q46542857 | ||
| Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. | Q46645214 | ||
| Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. | Q53115314 | ||
| Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. | Q53236215 | ||
| Combined therapy for cancer of the anal canal: a preliminary report | Q69769686 | ||
| Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research | Q71693075 | ||
| Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem | Q72061235 | ||
| Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and | Q73368699 | ||
| P921 | main subject | fluorouracil | Q238512 |
| capecitabine | Q420207 | ||
| squamous cell carcinoma | Q681817 | ||
| meta-analysis | Q815382 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 699 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Ecancermedicalscience | Q27722239 |
| P1476 | title | Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis | |
| P478 | volume | 10 |
| Q98164822 | Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center |
| Q92486851 | Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer |
| Q89612279 | Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy |
| Q61804239 | Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis |
Search more.